PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 or Fax (571) 273-2885

ISSUE FEE

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required) Blocks I through 5 should be completed with

appropriate. All further correspondence including the Patent, advance orders and noti indicated unless corrected below or directed otherwise in Block 1, by (a) specifying maintenance fee notifications.	fication of maintenance fees will be mailed to the current correspondence address; a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)	Note: A certificate of mailing can only be used for domestic mailings of th

GREGORY L. BRADLEY MEDRAD, INC. ONE MEDRAD DRIVE INDIANOLA, PA 15051

APPLICATION NO.

APPLN. TYPE

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

TOTAL FEE(S) DUE

DATE DUE

	Dawn M. Dedola	Dawn M. Dedola		
	40	aw m Wedol	(Signature)	
	February 27,	2009	(Date)	
FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO	

PUBLICATION FEE

10/668,673 09/23/2003 Mark Trocki CT/00-001 CIP D2 5595 Front-Loading Medical Injector Adapted to Releasably Engage TITLE OF INVENTION: A Syringe Regardless of the Orientation of the Syringe with Respect to the Injector

nonprovisional	NO	\$1510)	\$300		810	03/03/2009
EXAM	INER	ART UN	IT	CLASS-SUBCLASS	1		
MacNeill, H	Elizabeth	3767		604-031000			
 Change of correspondence address or indication of "Fee Address" (37 CFR 1363). Change of correspondence address (or Change of Correspondence Address form PTOSBIT22) attached. Tee Address' indication (or "Pee Address" Indication form PTOSBI47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.		member a		

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

SMALL ENTITY

PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) MEDRAD, INC. Indianola, Pennsylvania

Please check the appropriate assignee category or categories (will not be printed on the patent) : 🔲 Individual 🗹 Corporation or other private group entity 🗀 Government 4a The following fee(s) are enclosed: 4b. Payment of Fec(s):

Issue Fee A check in the amount of the fee(s) is enclosed. Dublication Fee (No small entity discount permitted)

Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies ☑ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 13-2530

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyouse other than the applicant; a registered attorney or agent; or the assignce or other party in interest as shown by the records gift be Indied States Patent and Indennity Office.

Date February 27, 2009 Authorized Signature Jill Denesvich Typed or printed name Registration No. 52810

This collection of information is equired by 3 F CFR 1311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is givened by 5 E LSC 2. The List This collection is estimated to the L2 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time w/ TSF 1.1st This collection is estimated to the L2 minutes to complete, including gathering, preparing, and is form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginal 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginal 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.